Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report

Accepted/In Press date: 7 June 2021

Published date: 22 July 2021

Additional Information: Funding Information: CAN-BIND is an Integrated Discovery Program carried out in partnership with, and financial support from, the Ontario Brain Institute, an independent non-profit corporation, funded partially by the Ontario government. The opinions, results and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding is provided by the Canadian Institutes of Health Research (CIHR), Lundbeck, Bristol-Myers Squibb, Pfizer, and Servier. Funding and/or in kind support is also provided by the investigators’ universities and academic institutions. All study medications are independently purchased at wholesale market values. This work was also supported by the Medical Research Council and National Institute for Health Research [grant number MC_PC_12025] and infrastructure support was provided by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC). G.C. is supported by the MRC (grant number MR/N014103/1). Funding Information: R.W.L. has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Hansoh, Healthy Minds Canada, Janssen, Lundbeck, Lundbeck Institute, Michael Smith Foundation for Health Research, MITACS, Myriad Neuroscience, Ontario Brain Institute, Otsuka, Pfizer, St. Jude Medical, University Health Network Foundation, and VGH-UBCH Foundation. R.V.M. has received consulting and speaking honoraria from Allergan, Janssen, KYE, Lundbeck, Otsuka, and Sunovion, and research grants from CAN-BIND, CIHR, Janssen, Lallemand, Lundbeck, Nubiyota, OBI and OMHF. B.N.F. received a research grant from Pfizer. SHK has received research funding or honoraria from the following sources: Abbott, Alkermes, Allergan, Boehringer-Ingelheim, Brain Canada, Canadian Institutes of Health Research (CIHR), Janssen, Lundbeck, Lundbeck Institute, Ontario Mental Health Foundation (OMHF), Ontario Brain Institute, Ontario Research Fund (ORF), Otsuka, Pfizer, Sanofi, Servier, St. Jude Medical, Sun Pharmaceuticals, and Sunovion. The remaining authors declare that there is no competing interests. Funding Information: The data produced and used in this study are supported by The Canadian Biomarker Integration Network in Depression (CAN-BIND, https://canbind.ca/), which is an Integrative Discovery Program funded by the Ontario Brain Institute (OBI, https:// braininstitute.ca/). In accordance with the Research Activity Agreements between CAN-BIND and OBI, data produced in this study must be submitted to Brain-CODE (https:// www.braincode.ca/), an informatic platform created by the OBI to facilitate open-access of data generated from research funded by the OBI. Researchers requesting Data will provide OBI with written documentation of the proposed use of the Data in the form of an Research Ethics Board (REB) approval package which includes the full REB submission package and REB approval letter from their local Institutional REB. Should the REB determine that ethics review is not required, an exemption letter from the REB will be required. If the External Researcher is from an Institution that does not have a local REB, OBI will work with the External Researcher to identify a mutually acceptable REB for review. All documents not in English or French will require a certified translation copy. For detailed data access policy and procedure, please refer https://www. braininstitute.ca/research-data-sharing/brain-code or contact help@braincode.ca. Otherwise, data points underlying Figs. 2b, 3b, and 4b are presented in Supplementary Data 5–7. Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Local EPrints ID: 453473

URI: http://eprints.soton.ac.uk/id/eprint/453473

DOI: doi:10.1038/s42003-021-02421-6

ISSN: 2399-3642

PURE UUID: be7b5525-1993-43e1-b407-28c6ef3499ea

ORCID for Jonathan R. Swann: orcid.org/0000-0002-6485-4529

Date deposited: 18 Jan 2022 17:37

Last modified: 18 Mar 2024 03:56